Sandoz is the global leader in generics and biosimilar medicines, with a growth strategy driven by its Purpose: pioneering access for patients. More than 20,000 people of 100 nationalities work together to ensure 900 million patient treatments are provided by Sandoz, generating substantial global healthcare savings and an even larger social impact. Our leading global portfolio of approximately 1,300 products addresses diseases from the common cold to cancer. Sandoz traces its global heritage back to 1886. Its history of breakthroughs includes Calcium Sandoz in 1929, the world’s first oral penicillin in 1951, and the world’s first biosimilar in 2006. In 2024, Sandoz recorded net sales of USD 10.4 billion. We are present in more than 100 countries, and our medicines serve some 500 million people every year. At Sandoz US, headquartered in Princeton, NJ, we build on our global legacy to deliver the high-quality, affordable medicines that Americans depend on. These include both Generics - divided between standard generics and complex generics - and Biosimilars, which we introduced to the US with the launch of the first FDA-approved biosimilar in 2015. Our 400+ associates across the US work collaboratively to champion a competitive and sustainable healthcare system so that patients can access the medicines they need, when they need them. Our mission is clear: to break down barriers, drive innovation, and deliver sustainable solutions that put patients first.